JP2005500266A5 - - Google Patents
Info
- Publication number
- JP2005500266A5 JP2005500266A5 JP2002590924A JP2002590924A JP2005500266A5 JP 2005500266 A5 JP2005500266 A5 JP 2005500266A5 JP 2002590924 A JP2002590924 A JP 2002590924A JP 2002590924 A JP2002590924 A JP 2002590924A JP 2005500266 A5 JP2005500266 A5 JP 2005500266A5
- Authority
- JP
- Japan
- Prior art keywords
- substituted
- alkyl
- heterocycle
- arylalkyl
- aryl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 125000000623 heterocyclic group Chemical group 0.000 claims 215
- 125000003710 aryl alkyl group Chemical group 0.000 claims 180
- 229910052739 hydrogen Inorganic materials 0.000 claims 128
- 239000001257 hydrogen Substances 0.000 claims 128
- 150000001875 compounds Chemical class 0.000 claims 115
- 125000000217 alkyl group Chemical group 0.000 claims 95
- 125000003118 aryl group Chemical group 0.000 claims 91
- 125000000547 substituted alkyl group Chemical group 0.000 claims 90
- 150000002431 hydrogen Chemical class 0.000 claims 87
- 125000003107 substituted aryl group Chemical group 0.000 claims 71
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 54
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 41
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims 39
- 229910052760 oxygen Inorganic materials 0.000 claims 39
- 239000001301 oxygen Substances 0.000 claims 39
- 125000005343 heterocyclic alkyl group Chemical group 0.000 claims 32
- 229910052736 halogen Inorganic materials 0.000 claims 17
- 150000002367 halogens Chemical class 0.000 claims 17
- 229910052757 nitrogen Inorganic materials 0.000 claims 17
- 125000004433 nitrogen atom Chemical group N* 0.000 claims 17
- 239000003814 drug Substances 0.000 claims 14
- 239000000651 prodrug Substances 0.000 claims 13
- 229940002612 prodrug Drugs 0.000 claims 13
- 150000003839 salts Chemical class 0.000 claims 13
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims 12
- 229910052717 sulfur Chemical group 0.000 claims 12
- 239000011593 sulfur Chemical group 0.000 claims 12
- 241001465754 Metazoa Species 0.000 claims 10
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 9
- 239000003112 inhibitor Substances 0.000 claims 8
- 229910052794 bromium Inorganic materials 0.000 claims 6
- 229910052801 chlorine Inorganic materials 0.000 claims 6
- 229910052740 iodine Inorganic materials 0.000 claims 6
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims 5
- 125000004103 aminoalkyl group Chemical group 0.000 claims 4
- 239000003795 chemical substances by application Substances 0.000 claims 4
- 230000000694 effects Effects 0.000 claims 4
- 238000000034 method Methods 0.000 claims 4
- 229920001184 polypeptide Polymers 0.000 claims 4
- 102000004196 processed proteins & peptides Human genes 0.000 claims 4
- 108090000765 processed proteins & peptides Proteins 0.000 claims 4
- LMBFAGIMSUYTBN-MPZNNTNKSA-N teixobactin Chemical compound C([C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H](CCC(N)=O)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H]1C(N[C@@H](C)C(=O)N[C@@H](C[C@@H]2NC(=N)NC2)C(=O)N[C@H](C(=O)O[C@H]1C)[C@@H](C)CC)=O)NC)C1=CC=CC=C1 LMBFAGIMSUYTBN-MPZNNTNKSA-N 0.000 claims 4
- 208000023275 Autoimmune disease Diseases 0.000 claims 2
- 208000006673 asthma Diseases 0.000 claims 2
- 208000027866 inflammatory disease Diseases 0.000 claims 2
- 206010001052 Acute respiratory distress syndrome Diseases 0.000 claims 1
- 206010061218 Inflammation Diseases 0.000 claims 1
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 208000010067 Pituitary ACTH Hypersecretion Diseases 0.000 claims 1
- 208000020627 Pituitary-dependent Cushing syndrome Diseases 0.000 claims 1
- 208000013616 Respiratory Distress Syndrome Diseases 0.000 claims 1
- 206010040070 Septic Shock Diseases 0.000 claims 1
- 201000000028 adult respiratory distress syndrome Diseases 0.000 claims 1
- 230000033115 angiogenesis Effects 0.000 claims 1
- 206010003246 arthritis Diseases 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 206010012601 diabetes mellitus Diseases 0.000 claims 1
- -1 dialkyl Chemical group 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 108020001507 fusion proteins Proteins 0.000 claims 1
- 102000037865 fusion proteins Human genes 0.000 claims 1
- 239000003862 glucocorticoid Substances 0.000 claims 1
- 125000004404 heteroalkyl group Chemical group 0.000 claims 1
- 230000028993 immune response Effects 0.000 claims 1
- 230000004054 inflammatory process Effects 0.000 claims 1
- 239000003550 marker Substances 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 201000006417 multiple sclerosis Diseases 0.000 claims 1
- 201000008482 osteoarthritis Diseases 0.000 claims 1
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 1
- 238000012216 screening Methods 0.000 claims 1
- 230000036303 septic shock Effects 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US29364201P | 2001-05-24 | 2001-05-24 | |
| PCT/US2002/016963 WO2002094203A2 (en) | 2001-05-24 | 2002-05-24 | Inhibitors of macrophage migration inhibitory factor and methods for identifying the same |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2005500266A JP2005500266A (ja) | 2005-01-06 |
| JP2005500266A5 true JP2005500266A5 (enExample) | 2005-12-15 |
| JP4346312B2 JP4346312B2 (ja) | 2009-10-21 |
Family
ID=23129922
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2002590924A Expired - Fee Related JP4346312B2 (ja) | 2001-05-24 | 2002-05-24 | マクロファージ遊走阻止因子インヒビターおよびそれを同定する方法 |
Country Status (24)
| Country | Link |
|---|---|
| US (14) | US7105519B2 (enExample) |
| EP (1) | EP1389110B1 (enExample) |
| JP (1) | JP4346312B2 (enExample) |
| KR (1) | KR100896973B1 (enExample) |
| CN (1) | CN1523989A (enExample) |
| AR (1) | AR036032A1 (enExample) |
| AT (1) | ATE461920T1 (enExample) |
| AU (2) | AU2002303906B2 (enExample) |
| BR (1) | BR0209948A (enExample) |
| CA (1) | CA2447103A1 (enExample) |
| CZ (1) | CZ20033503A3 (enExample) |
| DE (1) | DE60235750D1 (enExample) |
| ES (1) | ES2342877T3 (enExample) |
| HU (1) | HUP0500101A3 (enExample) |
| IL (1) | IL158550A0 (enExample) |
| MX (1) | MXJL03000038A (enExample) |
| MY (1) | MY140679A (enExample) |
| NZ (1) | NZ529244A (enExample) |
| PL (1) | PL367127A1 (enExample) |
| PT (1) | PT1389110E (enExample) |
| RU (1) | RU2327695C2 (enExample) |
| UY (1) | UY27304A1 (enExample) |
| WO (1) | WO2002094203A2 (enExample) |
| ZA (1) | ZA200309738B (enExample) |
Families Citing this family (51)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP4202763B2 (ja) | 2001-03-29 | 2008-12-24 | サイトカイン・ファーマサイエンシズ・インコーポレーテッド | マクロファージ遊走阻止因子レセプターとしてのｍｈｃクラスｉｉ不変鎖ポリペプチド使用のための方法及び組成物 |
| UY27304A1 (es) * | 2001-05-24 | 2002-12-31 | Avanir Pharmaceuticals | Inhibidores del factor inhibidor de la migración de los macrófagos y métodos para su identificación |
| US20030195192A1 (en) * | 2002-04-05 | 2003-10-16 | Fortuna Haviv | Nicotinamides having antiangiogenic activity |
| US20040014744A1 (en) * | 2002-04-05 | 2004-01-22 | Fortuna Haviv | Substituted pyridines having antiangiogenic activity |
| EP1500402A4 (en) | 2002-04-26 | 2009-12-30 | Takeda Pharmaceutical | INHIBITOR OF CELL DEATH |
| CA2489560A1 (en) * | 2002-06-27 | 2004-01-08 | Schering Aktiengesellschaft | Substituted quinoline ccr5 receptor antagonists |
| TW200418829A (en) * | 2003-02-14 | 2004-10-01 | Avanir Pharmaceutics | Inhibitors of macrophage migration inhibitory factor and methods for identifying the same |
| TWI328009B (en) | 2003-05-21 | 2010-08-01 | Glaxo Group Ltd | Quinoline derivatives as phosphodiesterase inhibitors |
| GB0316915D0 (en) | 2003-07-18 | 2003-08-20 | Glaxo Group Ltd | Compounds |
| US7364869B2 (en) * | 2003-07-29 | 2008-04-29 | The J. David Gladstone Institutes | Method of detecting antigen-specific T lymphocytes |
| JP2007503388A (ja) * | 2003-08-22 | 2007-02-22 | アバニール・ファーマシューティカルズ | マクロファージ遊走阻止因子の阻害剤としての置換ナフチリジン誘導体、およびヒト疾患の治療におけるそれらの使用 |
| US7592466B2 (en) | 2003-10-09 | 2009-09-22 | Abbott Laboratories | Ureas having antiangiogenic activity |
| AU2011265309B2 (en) * | 2003-11-21 | 2014-06-05 | Array Biopharma, Inc. | AKT protein kinase inhibitors |
| AU2004293026B2 (en) | 2003-11-21 | 2012-01-19 | Array Biopharma Inc. | AKT protein kinase inhibitors |
| US20080305118A1 (en) * | 2004-03-29 | 2008-12-11 | The Feinstein Institute For Medical Research | Treatment Of Type 1 Diabetes With Inhibitors Of Macrophage Migration Inhibitory Factor |
| DE102004029573A1 (de) * | 2004-06-18 | 2005-12-29 | Gambro Lundia Ab | MIF-Adsorbent |
| AU2004323369A1 (en) * | 2004-09-17 | 2006-03-23 | Siang Beng Chng | System and method for batch conversion of RFID tag to RFID label |
| WO2006102191A1 (en) * | 2005-03-24 | 2006-09-28 | Avanir Pharmaceuticals | Thienopyridinone derivatives as macrophage migration inhibitory factor inhibitors |
| EP1928438B1 (en) * | 2005-09-26 | 2013-03-20 | Avigen, Inc. | Use of ibudilast for treating drug addictions |
| GB0605689D0 (en) * | 2006-03-21 | 2006-05-03 | Novartis Ag | Organic compounds |
| WO2007112036A2 (en) * | 2006-03-24 | 2007-10-04 | The Feinstein Institute For Medical Research | Modified macrophage migration inhibitory factor inhibitors |
| CN100457895C (zh) * | 2006-05-24 | 2009-02-04 | 中国科学院生物物理研究所 | 鼠抗人巨噬细胞迁移抑制因子单克隆抗体及其应用 |
| WO2007142923A1 (en) * | 2006-05-31 | 2007-12-13 | Avigen, Inc. | Mif inhibitors for treating neuropathic pain and associated syndromes |
| EP2026804A1 (en) * | 2006-05-31 | 2009-02-25 | Avigen, Inc. | Ibudilast for inhibiting macrophage migration inhibitory factor (mif) activity |
| US7845914B2 (en) * | 2007-02-15 | 2010-12-07 | Deere & Company | Self-priming fast fill sprayer pump system |
| WO2009045543A1 (en) * | 2007-10-04 | 2009-04-09 | The Regents Of The University Of California | Treatment of conditions related to shock |
| US9643922B2 (en) | 2008-08-18 | 2017-05-09 | Yale University | MIF modulators |
| US9540322B2 (en) | 2008-08-18 | 2017-01-10 | Yale University | MIF modulators |
| EP2198879A1 (en) | 2008-12-11 | 2010-06-23 | Institut Curie | CD74 modulator agent for regulating dendritic cell migration and device for studying the motility capacity of a cell |
| WO2012009649A1 (en) * | 2010-07-16 | 2012-01-19 | Anderson Gaweco | Mif inhibitors and their uses |
| GB2497476B (en) * | 2010-09-06 | 2018-01-10 | Guangzhou Inst Biomed & Health | Amide Compounds |
| US9295715B2 (en) | 2010-10-02 | 2016-03-29 | The Regents Of The University Of California | Minimizing intestinal dysfunction |
| AU2012320597C1 (en) | 2011-10-07 | 2015-10-15 | Baxalta GmbH | oxMIF as a diagnostic marker |
| KR20130118612A (ko) * | 2012-04-20 | 2013-10-30 | (주)네오믹스 | 신규한 아미노피리딘 유도체 및 이의 용도 |
| CA3095012C (en) | 2012-05-01 | 2023-02-07 | Translatum Medicus Inc. | Methods for treating and diagnosing blinding eye diseases |
| US9549988B2 (en) | 2013-06-09 | 2017-01-24 | RJS Biologics | Pharmaceutical compounds targeted by MIF affinity-tethered moieties |
| WO2016057702A2 (en) | 2014-10-07 | 2016-04-14 | Cornell University | Methods for prognosing and preventing metastatic liver disease |
| HK1249105A1 (zh) * | 2015-07-17 | 2018-10-26 | 富士胶片富山化学株式会社 | 含氮杂环化合物 |
| CN111406050B (zh) * | 2018-01-17 | 2023-02-03 | 厦门宝太生物科技股份有限公司 | 吲哚胺2,3-双加氧酶抑制剂及其用途 |
| KR20210009315A (ko) | 2018-04-11 | 2021-01-26 | 오하이오 스테이트 이노베이션 파운데이션 | 안약 전달용 서방형 마이크로 입자를 이용한 방법 및 조성물 |
| IL296734B2 (en) | 2018-04-13 | 2025-06-01 | The Institute Of Cancer Res Royal Cancer Hospital | Bcl6 inhibitors |
| SG11202012973RA (en) | 2018-06-27 | 2021-01-28 | Bristol Myers Squibb Co | Naphthyridinone compounds useful as t cell activators |
| CN112654621B (zh) | 2018-06-27 | 2024-05-14 | 百时美施贵宝公司 | 可作为t细胞活化剂的经取代萘啶酮化合物 |
| AR119821A1 (es) | 2019-08-28 | 2022-01-12 | Bristol Myers Squibb Co | Compuestos de piridopirimidinonilo sustituidos útiles como activadores de células t |
| GB201914860D0 (en) | 2019-10-14 | 2019-11-27 | Cancer Research Tech Ltd | Inhibitor compounds |
| MX2022007369A (es) * | 2019-12-23 | 2022-07-12 | Bristol Myers Squibb Co | Compuestos de quinolinonilo piperazina sustituidos utiles como activadores de celulas t. |
| CA3162979A1 (en) | 2019-12-23 | 2021-07-01 | Upender Velaparthi | Substituted piperazine derivatives useful as t cell activators |
| AR120823A1 (es) | 2019-12-23 | 2022-03-23 | Bristol Myers Squibb Co | Compuestos bicíclicos sustituidos útiles como activadores de células t |
| IL294148A (en) | 2019-12-23 | 2022-08-01 | Bristol Myers Squibb Co | Substituted quinazolinyl compounds are useful as t-cell activators |
| CN113121435B (zh) * | 2021-04-20 | 2022-08-30 | 辽宁大学 | 一种2,4-二氯喹啉类化合物的合成方法 |
| CN119074725B (zh) * | 2024-09-11 | 2026-03-17 | 北京大学第一医院(北京大学第一临床医学院) | 靶向mif在制备用于治疗特应性皮炎的药物中应用 |
Family Cites Families (59)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4324893A (en) | 1979-04-18 | 1982-04-13 | American Home Products Corporation | 4-Amino-3-carboxy or cyano-1,2-dihydro-2-oxo-1,8-naphthyridine derivatives |
| US4299814A (en) | 1979-05-25 | 1981-11-10 | Monsanto Company | Radioimmunoassay of MIF |
| US4284768A (en) * | 1980-07-02 | 1981-08-18 | American Home Products Corporation | 1,2-Dihydro-4-amino-2-oxo-3-quinoline-carboxylic acid derivatives |
| CA1340103C (en) | 1984-02-22 | 1998-10-27 | Karel Gerrit Odink | Cloning of dna for protozoal antigens |
| US5733524A (en) | 1984-03-19 | 1998-03-31 | The Picower Institute For Medical Research | Methods and materials for the diagnosis and treatment of conditions such as stroke |
| US5869534A (en) | 1992-05-21 | 1999-02-09 | The Picower Institute For Medical Research | Glycosylation of lipids and lipid-containing particles, and diagnostic and therapeutic methods and materials derived therefrom |
| US5801200A (en) | 1984-03-19 | 1998-09-01 | The Picower Institute For Medical Research | Methods and materials for the diagnosis and treatment of conditions such as stroke |
| US5733933A (en) | 1984-03-19 | 1998-03-31 | The Picower Institute For Medical Research | Methods and materials for the diagnosis and treatment of conditions such as stroke |
| US5700447A (en) | 1992-05-21 | 1997-12-23 | The Picowder Institute For Medical Research | Methods and materials for the diagnosis and treatment of conditions such as stroke |
| AU592753B2 (en) | 1984-05-24 | 1990-01-25 | Ciba-Geigy Ag | Lymphokine in pure foem, novel monoclonal antibodies hybridoma cell lines, processes and applications |
| JPH0672158B2 (ja) | 1984-05-24 | 1994-09-14 | チバ−ガイギ− アクチエンゲゼルシヤフト | 精製されたヒトマクロファージ遊走阻止因子 |
| US4708937A (en) | 1984-10-15 | 1987-11-24 | Brigham & Women's Hospital | Purified migration inhibitory factor also having colony stimulating factor activity |
| US4683202A (en) | 1985-03-28 | 1987-07-28 | Cetus Corporation | Process for amplifying nucleic acid sequences |
| GB8602626D0 (en) | 1986-02-04 | 1986-03-12 | Ciba Geigy Ag | Neurite-promoting factor |
| DE3789413T2 (de) | 1986-10-03 | 1994-07-28 | Ciba Geigy Ag | Lymphokin-ähnliche Peptide. |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| WO1990011301A1 (en) | 1989-03-17 | 1990-10-04 | Genetics Institute, Inc. | Human macrophage migration inhibitory factor |
| FI82144C (fi) | 1989-03-22 | 1991-01-10 | Wallac Oy | Foerfarande foer samtidig bestaemning av flera ligander. |
| GB8915414D0 (en) | 1989-07-05 | 1989-08-23 | Ciba Geigy | Novel cytokines |
| KR0166088B1 (ko) | 1990-01-23 | 1999-01-15 | . | 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도 |
| US5328990A (en) | 1991-04-26 | 1994-07-12 | The United States Of America As Represented By The Department Of Health And Human Services | Isolation of macrophage migration inhibition factor from ocular lens |
| CA2054602C (en) | 1991-10-31 | 2003-04-22 | Anthony Pawson | Method for assaying for a substance that affects an sh2-phosphorylated ligand regulatory system |
| US5624804A (en) | 1991-12-20 | 1997-04-29 | The Rockefeller University | Immunochemical detection of In vivo advanced glycosylation end products |
| WO1994026307A1 (en) | 1993-05-17 | 1994-11-24 | The Picower Institute For Medical Research | Inhibition of migration inhibitory factor in the treatment of diseases involving cytokine-mediated toxicity |
| US6774227B1 (en) | 1993-05-17 | 2004-08-10 | Cytokine Pharmasciences, Inc. | Therapeutic uses of factors which inhibit or neutralize MIF activity |
| US6645493B1 (en) | 1993-05-17 | 2003-11-11 | The Picower Institute For Medical Research | Composition containing anti-MIF antibody |
| US5650295A (en) | 1995-06-02 | 1997-07-22 | Human Genone Sciences, Inc. | Macrophage migration inhibitory factor-3 |
| US6080408A (en) * | 1994-08-22 | 2000-06-27 | Connaught Laboratories Limited | Human immunodeficiency virus type 1 nucleic acids devoid of long terminal repeats capable of encoding for non-infectious, immunogenic, retrovirus-like particles |
| SI9400363A (en) | 1994-09-19 | 1996-08-31 | Mozetic Francky Bojana | Human macrophage migration inhibitory factor of nonlymphoid origin, expression of mif in e. coli and purification of recombinant protein |
| US5955203A (en) | 1994-10-05 | 1999-09-21 | Simpson Timber Company | Resin-coated overlays for solid substrates |
| WO1996015242A2 (en) | 1994-11-16 | 1996-05-23 | The Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services | Methods for inhibiting cell proliferation by inhibiting the mitogenic activity of macrophage migration inhibitory factor |
| DE19601697A1 (de) | 1996-01-18 | 1997-07-24 | Wacker Chemie Gmbh | Redispergierbare Tackifierpulver |
| US6420188B1 (en) | 1996-02-16 | 2002-07-16 | The Picower Institute For Medical Research | Screening assay for the identification of inhibitors for macrophage migration inhibitory factor |
| US6492428B1 (en) | 2000-07-26 | 2002-12-10 | The Picower Institute For Medical Research | Compounds having MIF antagonist activity |
| EP0898709A2 (en) | 1996-04-18 | 1999-03-03 | Ariad Pharmaceuticals, Inc. | $i(IN VITRO) FLUORESCENCE POLARIZATION ASSAY |
| US5883224A (en) | 1996-04-19 | 1999-03-16 | Cytokine Sciences, Inc. | Characterization of transfer factors and methods of use |
| US5919815A (en) | 1996-05-22 | 1999-07-06 | Neuromedica, Inc. | Taxane compounds and compositions |
| JPH1171351A (ja) * | 1997-08-29 | 1999-03-16 | Ss Pharmaceut Co Ltd | 置換キノロン誘導体及びこれを含有する医薬 |
| US6413939B1 (en) | 1997-10-31 | 2002-07-02 | The Picower Institute For Medical Research | Inducible phosphofructokinase and the Warburg effect |
| US6238874B1 (en) | 1998-07-28 | 2001-05-29 | Biometric Imaging, Inc. | Cell motility assay |
| CA2337100C (en) | 1998-08-07 | 2011-09-20 | Immunex Corporation | Polypeptides of lymphodendritic cell adhesion molecules (ldcams) and polynucleotides encoding the same |
| US6214343B1 (en) | 1999-05-24 | 2001-04-10 | Ophidian Pharmaceuticals, Inc. | Prevention and treatment of necrotizing enterocolitis |
| CA2389229A1 (en) | 1999-10-29 | 2001-05-10 | The Picower Institute For Medical Research | Compounds having mif antagonist activity |
| MXPA03006275A (es) | 2001-01-12 | 2005-09-08 | Cytokine Pharmasciences Inc | Metodo y composiciones para modular la regulacion de la respuesta de linfocitos citotoxicos por el factor inhibidor de la migracion de macrofagos. |
| JP4202763B2 (ja) | 2001-03-29 | 2008-12-24 | サイトカイン・ファーマサイエンシズ・インコーポレーテッド | マクロファージ遊走阻止因子レセプターとしてのｍｈｃクラスｉｉ不変鎖ポリペプチド使用のための方法及び組成物 |
| UY27304A1 (es) * | 2001-05-24 | 2002-12-31 | Avanir Pharmaceuticals | Inhibidores del factor inhibidor de la migración de los macrófagos y métodos para su identificación |
| EP1424336A4 (en) | 2001-09-03 | 2004-11-10 | Takeda Chemical Industries Ltd | 1,3-BENZOTHIAZINE DERIVATIVES AND THEIR USE |
| FR2829491B1 (fr) | 2001-09-12 | 2005-09-30 | Diverchim | Procede de preparation des hydroxy-acides gras insatures et de leurs esters, leur utilisation comme agent anti-collagenase |
| AU2002365941A1 (en) | 2001-12-05 | 2003-09-02 | North Shore-Long Island Jewish Research Institute | Methods of diagnosis, monitoring and treatment of fertility |
| US20040019921A1 (en) | 2001-12-19 | 2004-01-29 | Fingerle-Rowson Gunter R. | Non-human mammal with disrupted or modified MIF gene, and uses thereof |
| EP1500402A4 (en) | 2002-04-26 | 2009-12-30 | Takeda Pharmaceutical | INHIBITOR OF CELL DEATH |
| WO2003104178A1 (en) | 2002-06-07 | 2003-12-18 | Cortical Pty Ltd | Napththalene derivatives which inhibit the cytokine or biological activity of macrophage migration inhibitory factor (mif) |
| EP2319838A1 (en) | 2002-06-07 | 2011-05-11 | Cortical Pty Ltd | Therapeutic Molecules and Methods-1 |
| JP2006502236A (ja) | 2002-09-18 | 2006-01-19 | ファイザー・プロダクツ・インク | 形質転換成長因子（ｔｇｆ）阻害剤としてのトリアゾール誘導体 |
| WO2004060881A1 (ja) | 2002-12-05 | 2004-07-22 | Takeda Pharmaceutical Company Limited | １，３−ベンゾチアジノン誘導体、その製造法および用途 |
| TW200418829A (en) | 2003-02-14 | 2004-10-01 | Avanir Pharmaceutics | Inhibitors of macrophage migration inhibitory factor and methods for identifying the same |
| US7361474B2 (en) | 2003-02-24 | 2008-04-22 | United States Of America As Represented By The Department Of Veterans Affairs | Serum macrophage migration inhibitory factor (MIF) as marker for prostate cancer |
| JP2007503388A (ja) * | 2003-08-22 | 2007-02-22 | アバニール・ファーマシューティカルズ | マクロファージ遊走阻止因子の阻害剤としての置換ナフチリジン誘導体、およびヒト疾患の治療におけるそれらの使用 |
| WO2006102191A1 (en) * | 2005-03-24 | 2006-09-28 | Avanir Pharmaceuticals | Thienopyridinone derivatives as macrophage migration inhibitory factor inhibitors |
-
2002
- 2002-05-23 UY UY27304A patent/UY27304A1/es not_active Application Discontinuation
- 2002-05-23 MY MYPI20021922A patent/MY140679A/en unknown
- 2002-05-24 CZ CZ20033503A patent/CZ20033503A3/cs unknown
- 2002-05-24 ES ES02731971T patent/ES2342877T3/es not_active Expired - Lifetime
- 2002-05-24 CA CA002447103A patent/CA2447103A1/en not_active Abandoned
- 2002-05-24 US US10/156,650 patent/US7105519B2/en not_active Expired - Fee Related
- 2002-05-24 AU AU2002303906A patent/AU2002303906B2/en not_active Ceased
- 2002-05-24 AT AT02731971T patent/ATE461920T1/de active
- 2002-05-24 HU HU0500101A patent/HUP0500101A3/hu unknown
- 2002-05-24 PT PT02731971T patent/PT1389110E/pt unknown
- 2002-05-24 IL IL15855002A patent/IL158550A0/xx unknown
- 2002-05-24 PL PL02367127A patent/PL367127A1/xx unknown
- 2002-05-24 JP JP2002590924A patent/JP4346312B2/ja not_active Expired - Fee Related
- 2002-05-24 RU RU2003132534/04A patent/RU2327695C2/ru not_active IP Right Cessation
- 2002-05-24 AR ARP020101966A patent/AR036032A1/es unknown
- 2002-05-24 KR KR1020037015359A patent/KR100896973B1/ko not_active Expired - Fee Related
- 2002-05-24 NZ NZ529244A patent/NZ529244A/en unknown
- 2002-05-24 WO PCT/US2002/016963 patent/WO2002094203A2/en not_active Ceased
- 2002-05-24 MX MXJL03000038A patent/MXJL03000038A/es active IP Right Grant
- 2002-05-24 BR BR0209948-9A patent/BR0209948A/pt not_active Application Discontinuation
- 2002-05-24 CN CNA02810501XA patent/CN1523989A/zh active Pending
- 2002-05-24 EP EP02731971A patent/EP1389110B1/en not_active Expired - Lifetime
- 2002-05-24 DE DE60235750T patent/DE60235750D1/de not_active Expired - Lifetime
-
2003
- 2003-12-17 ZA ZA200309738A patent/ZA200309738B/xx unknown
-
2005
- 2005-07-15 US US11/182,360 patent/US7514225B2/en not_active Expired - Fee Related
- 2005-07-15 US US11/182,241 patent/US7732146B2/en not_active Expired - Fee Related
- 2005-11-07 US US11/268,375 patent/US7084141B2/en not_active Expired - Fee Related
-
2006
- 2006-01-31 US US11/344,938 patent/US7202248B2/en not_active Expired - Fee Related
- 2006-05-02 US US11/415,628 patent/US7192961B2/en not_active Expired - Fee Related
- 2006-05-02 US US11/415,842 patent/US7238809B2/en not_active Expired - Fee Related
- 2006-05-02 US US11/415,552 patent/US7235565B2/en not_active Expired - Fee Related
- 2006-05-02 US US11/415,785 patent/US7192955B2/en not_active Expired - Fee Related
- 2006-05-02 US US11/415,998 patent/US7129236B2/en not_active Expired - Fee Related
- 2006-05-02 US US11/416,004 patent/US7157469B2/en not_active Expired - Fee Related
- 2006-05-02 US US11/416,165 patent/US7230106B2/en not_active Expired - Fee Related
- 2006-12-07 US US11/635,319 patent/US7435737B2/en not_active Expired - Fee Related
-
2007
- 2007-03-16 US US11/687,611 patent/US7432374B2/en not_active Expired - Fee Related
- 2007-04-04 AU AU2007201493A patent/AU2007201493A1/en not_active Abandoned